Board of Directors

Christopher M. Cashman

Christopher M. Cashman is Chairman of the Board of Directors, President and Chief Executive Officer of Marinus. Mr. Cashman is a recognized leader in the biopharmaceutical industry and has decades of experience leading life sciences companies. Before joining Marinus, Mr. Cashman was co-founder, President and CEO of Protez Pharmaceuticals, Inc., a company specializing in the development of antibiotics, which was acquired by Novartis. Prior to his time with Protez, Mr. Cashman was President and CEO of Message Pharmaceuticals, Inc., and held various leadership roles at both Pfizer, Inc., and SmithKline Beecham plc. Chris currently serves on the Board of Directors of Rapid Micro Biosystems, Inc., Noble Biomaterials, Inc., and MBF Therapeutics, Inc. Mr. Cashman holds a master’s degree in economics from Purdue University and a bachelor’s degree in business management from the University of Minnesota.

John M. Morrash.

Mr. Morrash is a Senior Financial Executive with over 32 years of diversified financial experience.  His last ten years have been the Chief Financial Officer and Sr. Vice President of Superior Group, Inc., West Conshohocken, PA.  Mr. Morrash has extensive experience in fund raising, financial analysis, planning, acquisitions, international finance, divestitures, product and plant rationalizations, and etc.  Mr. Morrash completed over 25 M&A and divesture transactions.

Mr. Morrash’s international experience includes active involvement in international business operations and M&A transactions in Ireland, England, Mexico, Canada, Belgium, Germany, Italy, Spain, Denmark and Brazil.  Over the course of his career he has worked with manufacturing and distribution companies, including: prescription pharmaceutical, medical/surgical, aerospace, power generation, oil and gas, automotive, material handling, and other durable goods.

Jie Du, Ph.D. 

Dr. Jie Du is a seasoned pharmaceutical executive and entrepreneur. She is one of the founders at Frontage Laboratories, which started its operations in 2001. Frontage has since grown into a multi national contract research organization (CRO), serving pharmaceutical clients in North America and Asia. After exiting her holdings at Frontage, she has been active as an angel investor of life science start-ups.  In 2009, Dr. Du founded JDP Therapeutics. She is leading JDP in becoming a significant player in pharmaceutical innovation and development.

Dr. Du’s pharmaceutical experience extends 25 years at Abbott, Merck and URL Pharma. During her tenure of increasing responsibilities at these companies, she led activities in pharmaceutical product development, project management, legal/patent strategies, product portfolio management, clinical development, and regulatory areas.  Dr. Du is a brilliant initiator on pharmaceutical strategies. Three of her patents (assigned to URL Pharma) were licensed to King/Pfizer. Prior to starting JDP Therapeutics, Dr. Du served as the Director of Scientific Affairs at URL Pharma, a specialty pharma company in Philadelphia.  

Dr. Du’s endless creativity has made her a renowned inventor of many U.S. and international patents.  Dr. Du earned her Ph.D. degree from School of Pharmacy at University of the Pacific in California.

Karen Hong, Ph.D.

Bio to follow

Jingang Wang.

Mr. Wang is the founder and General Manager of CoSci Med-Tech Co., Ltd.,  a well established pharmaceutical company based in Beijing China.  He is a recognized leader in the biopharmaceutical industry in China.  Mr. Wang has invested heavily in pharmaceutical start up companies in the the U.S. and Europe.  CoSci led the Series A investment in JDP Therapeutics in 2016, and has been a constant support for JDP's corporate and business development.